TY - JOUR
T1 - Corticobasal degeneration
T2 - A pathologically distinct 4R tauopathy
AU - Kouri, Naomi
AU - Whitwell, Jennifer L.
AU - Josephs, Keith A.
AU - Rademakers, Rosa
AU - Dickson, Dennis W.
N1 - Funding Information:
K. A. Josephs is supported by NIH grants R01-DC10367 and R01-AG37491. J. L. Whitwell is supported by NIH grant R21-AG38736. D. W. Dickson is supported by the Mayo Foundation (Robert E. Jacoby Professorship for Alzheimer’s Research), Mangurian Foundation, CurePSP The Society for Progressive Supranuclear Palsy and NIH grants P50-AG16574, P50-NS72187 and P01-AG17216.
PY - 2011/5
Y1 - 2011/5
N2 - Corticobasal degeneration (CBD) is a rare, progressive neurodegenerative disorder with onset in the 5th to 7th decade of life. It is associated with heterogeneous motor, sensory, behavioral and cognitive symptoms, which make its diagnosis difficult in a living patient. The etiology of CBD is unknown; however, neuropathological and genetic evidence supports a pathogenetic role for microtubule-associated protein tau. CBD pathology is characterized by circumscribed cortical atrophy with spongiosis and ballooned neurons; the distribution of these changes dictates the patient's clinical presentation. Neuronal and glial tau pathology is extensive in gray and white matter of the cortex, basal ganglia, diencephalon and rostral brainstem. Abnormal tau accumulation within astrocytes forms pathognomonic astrocytic plaques. The classic clinical presentation, termed corticobasal syndrome (CBS), comprises asymmetric progressive rigidity and apraxia with limb dystonia and myoclonus. CBS also occurs in conjunction with other diseases, including Alzheimer disease and progressive supranuclear palsy. Moreover, the pathology of CBD is associated with clinical presentations other than CBS, including Richardson syndrome, behavioral variant frontotemporal dementia, primary progressive aphasia and posterior cortical syndrome. Progress in biomarker development to differentiate CBD from other disorders has been slow, but is essential in improving diagnosis and in development of disease-modifying therapies.
AB - Corticobasal degeneration (CBD) is a rare, progressive neurodegenerative disorder with onset in the 5th to 7th decade of life. It is associated with heterogeneous motor, sensory, behavioral and cognitive symptoms, which make its diagnosis difficult in a living patient. The etiology of CBD is unknown; however, neuropathological and genetic evidence supports a pathogenetic role for microtubule-associated protein tau. CBD pathology is characterized by circumscribed cortical atrophy with spongiosis and ballooned neurons; the distribution of these changes dictates the patient's clinical presentation. Neuronal and glial tau pathology is extensive in gray and white matter of the cortex, basal ganglia, diencephalon and rostral brainstem. Abnormal tau accumulation within astrocytes forms pathognomonic astrocytic plaques. The classic clinical presentation, termed corticobasal syndrome (CBS), comprises asymmetric progressive rigidity and apraxia with limb dystonia and myoclonus. CBS also occurs in conjunction with other diseases, including Alzheimer disease and progressive supranuclear palsy. Moreover, the pathology of CBD is associated with clinical presentations other than CBS, including Richardson syndrome, behavioral variant frontotemporal dementia, primary progressive aphasia and posterior cortical syndrome. Progress in biomarker development to differentiate CBD from other disorders has been slow, but is essential in improving diagnosis and in development of disease-modifying therapies.
UR - http://www.scopus.com/inward/record.url?scp=79955824336&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79955824336&partnerID=8YFLogxK
U2 - 10.1038/nrneurol.2011.43
DO - 10.1038/nrneurol.2011.43
M3 - Review article
C2 - 21487420
AN - SCOPUS:79955824336
SN - 1759-4758
VL - 7
SP - 263
EP - 272
JO - Nature Reviews Neurology
JF - Nature Reviews Neurology
IS - 5
ER -